InvestorsHub Logo
Followers 128
Posts 2150
Boards Moderated 1
Alias Born 12/27/2007

Re: None

Thursday, 08/04/2016 10:22:14 AM

Thursday, August 04, 2016 10:22:14 AM

Post# of 648998
IGXT (MC $37 M) 2 FDA approvals coming + 2 new NDA Filings in 4Q = 1000% Potential...A REAL LIFETIME OPPORTUNITY GUYS

Undiscovered Intelgenx (IGXT) is definitely one of the most attractive and undervalued stock in the Biotech Sector . The Company has already 2 Drugs approved and another 2 Big Drugs close to FDA approval .BIG Partnership News could come any day for up to 3 Drugs for which IGXT got a Therm Sheet from a Global Pharma Company and there are another partnering discussion ongoing for 2 Drugs (see pipeline chart below) .Their unique Thin-film version of the Blockbuster Drug Cialis (Erectile Dysfunction) alone is worth $2-3 per share , NDA filing for the Drug coming before Year end .

IGXT has a ridiculous Market Cap of $35 Million which is a Big Joke for a Company with such a MEGA Product Pipeline , this Co has everything to be the next 10 Bagger minimum .GL


Intelgenx (IGXT) (IGX.V)

Market Cap: $37 Million
Cash: $2.1 Million
Price: $0.59

Burn-Rate: ~$300k per Quarter
Shares Out : 63.6 Million



Upcoming Milestones :


Big Partnership imminent :

•Announced a development and commercialization term sheet with a global pharmaceutical company for up to three products. If entered into, IntelGenx expects the definitive agreement to be finalized in the second quarter of 2016



Product :Rizaport (Migraine)
•European Mktg Approval–November 2015
•Planned USA submission to FDA Q4/2016
•Expected USA launch Q2/2017


Product :Tadalafil (Erectile Dysfunction) a better Oral thin-film version of Blockbuster Drug Cialis
•505(b)(2) USA NDA submission in Q4/2016
•Expected USA launch Q4/2017


Product :Indicated for Opioid Dependence
•Awaiting FDA approval
•According to IMS data, the oral film market for opioid dependence was worth more than $1.4B US in 2014.


IntelGenx Corp., today announced the recent initiation of a phase 1 clinical trial of montelukast, a unique drug repurposing opportunity for the treatment of degenerative diseases of the brain, such as: mild cognitive impairment and Alzheimers disease, the most prominent form of dementia. IntelGenx expects results from the phase 1 trial to be available in September 2016.








Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.